Business context and reporting period
Entity mismatch: The supplied filing is Cactus Ventures, Inc.’s Form 10-Q for the quarter ended March 31, 2012, not an Actinium Pharmaceuticals filing. Cactus describes itself as an inactive Nevada shell/blank-check company seeking a merger or other business combination. The interim financial statements are unaudited.
Financial performance and position
| Metric | Q1 2012 / March 31, 2012 | Comparable period / prior year-end |
|---|---|---|
| Revenue | $0 | $0 in Q1 2011 |
| Operating expenses | $8,416 | $2,680 in Q1 2011 |
| Interest expense | $1,212 | $1,325 in Q1 2011 |
| Net loss | $9,628 | $4,005 in Q1 2011 |
| Cash and total assets | $150 | $150 at December 31, 2011 |
| Total liabilities | $94,106 | $84,479 at December 31, 2011 |
| Related-party notes payable | $64,173 | $58,168 at December 31, 2011 |
| Shareholders’ deficit | $93,956 | $84,329 at December 31, 2011 |
| Operating cash flow | $(6,006) | $(4,120) in Q1 2011 |
Gross profit and margins are not meaningful because the company had no sales or cost of goods. Q1 operating cash outflow was offset by $6,006 of related-party financing, leaving cash unchanged. The filing reports a $29,783 working-capital deficiency.
Material changes versus the prior comparable period
Revenue remained zero. Expenses rose to $8,416 from $2,680, and the net loss increased to $9,628 from $4,005. Interest expense declined slightly. Compared with year-end 2011, liabilities and the shareholders’ deficit increased, while cash remained $150.
Outlook, risks and unusual items
- Management estimated expenses of approximately $20,000 for the next 12 months and expected advances from the president to fund operations, but gave no assurance that funding would be available.
- The company had no acquisition target in mind and reported no current acquisition negotiations. A 2011 non-binding letter of intent had a closing deadline no later than July 31, 2011; the filing does not report a completed transaction.
- Management disclosed substantial doubt about the company’s ability to continue as a going concern, citing negative working capital and shareholders’ deficit. Continued operation depends on raising funds and implementing a business plan.
- A business combination could involve significant share issuance and dilution. The company also identified competition, execution and financing risks; it had no employees, line of credit or material operating assets.
- No legal proceedings, unregistered equity sales or defaults upon senior securities were reported. Management said disclosure controls were effective and that there were no material changes in internal control over financial reporting.
Important facts for investors to verify
- Confirm the filing belongs to the intended issuer: its registrant is Cactus Ventures, Inc., not Actinium Pharmaceuticals.
- Verify current cash needs, the availability and terms of further related-party advances, and the status and terms of related-party notes and accrued interest.
- Check whether any business combination was pursued or completed after the expired 2011 letter-of-intent deadline, and assess potential dilution.
- Review the going-concern uncertainty and the company’s ability to meet liabilities with only $150 in reported cash.